Insulet Co. (NASDAQ:PODD) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank cut its holdings in Insulet Co. (NASDAQ:PODD) by 26.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,965 shares of the medical instruments supplier’s stock after selling 10,181 shares during the quarter. Toronto Dominion Bank’s holdings in Insulet were worth $4,965,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of PODD. Sunbelt Securities Inc. acquired a new position in Insulet in the first quarter valued at $29,000. Benjamin F. Edwards & Company Inc. acquired a new position in Insulet in the fourth quarter valued at $34,000. Jones Financial Companies Lllp acquired a new position in Insulet in the fourth quarter valued at $40,000. Lindbrook Capital LLC increased its stake in shares of Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after acquiring an additional 75 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in shares of Insulet during the fourth quarter worth about $43,000.

Insider Activity at Insulet

In related news, Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the transaction, the director now owns 35,586 shares of the company’s stock, valued at $6,779,488.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the transaction, the director now directly owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,931 shares of company stock valued at $2,636,286. Company insiders own 0.47% of the company’s stock.

Insulet Stock Up 1.3 %

Shares of NASDAQ PODD opened at $193.30 on Friday. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $283.00. The company has a market capitalization of $13.54 billion, a PE ratio of 58.58, a price-to-earnings-growth ratio of 3.48 and a beta of 1.16. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. The firm’s 50-day moving average is $193.24 and its two-hundred day moving average is $184.60.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 earnings per share. Equities analysts anticipate that Insulet Co. will post 3.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PODD. Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a research note on Tuesday, May 7th. OTR Global reiterated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Barclays dropped their price target on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research note on Monday, May 13th. Jefferies Financial Group boosted their price target on shares of Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Finally, Raymond James dropped their price target on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $239.18.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.